Eric Dean, MD
Medical Oncology · Kirkland, WANPI 1366632671
Payments from drug & device makers
Across 8 payments — averaging $6161.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$49K
- Merck$518
- EMD Serono, Inc.$27
- Myovant Sciences Inc.$24
- Gilead$12
What the payments were for
- Food & beverage$2733%
- Education$5467%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 3 | $48,711 |
| Merck | 2 | $518 |
| EMD Serono, Inc. | 1 | $27 |
| Myovant Sciences Inc. | 1 | $24 |
| Gilead | 1 | $12 |
How this compares
$49,291 in reported general payments places this provider in the 45th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $287,442 |
| CalquenceAcalabrutinib Maleate | 13 | $213,917 |
| ImbruvicaIbrutinib | 13 | $207,833 |
| Abiraterone Acetate | 173 | $101,038 |
| Imatinib Mesylate | 14 | $64,020 |
| EliquisApixaban | 30 | $30,940 |
| Prednisone | 185 | $687 |
| Oxycodone Hcl | 35 | $533 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $455 |
| Acyclovir | 43 | $400 |
| Dexamethasone | 28 | $367 |
| Prochlorperazine Maleate | 28 | $356 |
| Potassium Chloride | 31 | $355 |
| Hydroxyurea | 13 | $313 |
| Ondansetron Hcl | 23 | $274 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Kirkland
- Michael SchweizerSeattle$27.4M
- Ajay GopalSeattle$14.6M
- Scott TykodiSeattle$14.2M
- Evan YuSeattle$9.8M
- Christina BaikSeattle$9M
- David MaloneySeattle$8.5M
- Shailender BhatiaSeattle$7.5M
- Andrew CovelerSeattle$7.1M
- William BensingerLakewood$6.9M
- Jennifer SpechtSeattle$6.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.